Journal of Nanomedicine & Nanotechnology

Nanotechnology and cardiovascular diseases

26^th International Conference on ADVANCED NANOSCIENCE AND NANOTECHNOLOGY

December 05-06, 2022 | Dubai, UAE

Omer Iqbal

Loyola University Stritch School of Medicine, USA

Keynote: J Nanomed Nanotechnol

Abstract:

Cardiovascular diseases are the leading cause of death globally with an estimated 17.9 million people who died in 2019, representing 32% of all global deaths. While an estimated 85% of these deaths are due to acute myocardial infarction and stroke, most cardiovascular diseases could be preventable, by addressing behavioral risk factors. The low levels of biomarkers released following myocardial ischemia, which may pose diagnostic challenge could be overcome by combining nanotechnologies with biosensors to ensure detection of disease at an early stage. Endothelium is by far the largest endocrine, autocrine and paracrine gland known. The main cause of coronary artery disease is development of atherosclerosis. Endothelial activation and endothelial dysfunction could trigger atherosclerosis and athero-thromboembolism. Early identification of atherogenesis through advanced nanoprobes for molecular imaging could be crucial in its prevention and progression. It is reported that cell surface receptor, CD44, overexpressed on atherosclerotic plaques could be bound by synthesis of nanoparticles of bioactive polymer hyaluronan with atorvastatin cores (HA-ATV-NPs ). Nanomaterials may be used to prevent or slow the progression of atherosclerosis into development of atherosclerotic plaques and vulnerable plaques by controlling endothelial activation, inflammation. Oxidative stress, restricting platelet recruitment. Nano silver by accumulating in platelet granules has been reported to show reduction in interplatelet proximity and show antiplatelet properties by preventing platelet aggregation. Nanomaterials such as poly (lactide-co-glycolide) and poly (lactic acid) and others have been reported to carry thrombolytic drugs and provide site directed nano thrombolysis. Nanotechnology-based targeted anticoagulant drug delivery to complement clot lysis have shown to be safer without affecting healthy blood vessels. Nanomaterials can reach the blood circulation and cause platelet activation and activation of coagulation that may be especially harmful to patients suffering from hypercoagulable states linked to diabetes, arteriosclerosis cancer and obstructive pulmonary disease. Mechanism of nanomaterial-induced procoagulant effects will be discussed.
Recent publications :
1. Hongyin Ma, Zhenmin Jiang and Zhen-Ni-Guo. Targeted nanodelivery strategies for facilitating thrombolysis treatment in ischemic stroke. Drug Delivery (2021), Vol 28, No. 1, 357- 371.
2. Toole BP (2004). Hyaluronan:from extracellular glue to pericellular cue. Nat Rev Cancer 4, 528- 539.
3. Shrivastava S, Bera T, Singh S, et al (2009). Characterization of antipatelet properties of silver nanoparticles. ACS Nano 3, 1357- 1364.

Biography :

Omer Iqbal is currently working as a research professor in the Departments of Ophthalmology and Pathology. He is an elected fellow of the American College of Cardiology FACC) and European Society of Cardiology (FESC). His interests are wide and varied including Personalized Medicine, Hemostasis and Thrombosis, Anticoagulation, Nanotechnology, Age related Macular Degeneration, Keratoconus, Culture in Medicine, History of Medicine and Stevens Johnson Syndrome/Toxic Epidermal Necrolysis. For over three decades he has been actively engaged in research related to Hemostasis & Thrombosis and point-of-care monitoring of New Oral Anticoagulant Drugs (NOAD). He is a professional member of various National and International Societies including, American College of Cardiology, European Society of Cardiology, International Society of Hemostasis and Thrombosis, American Heart Association and American Society of Clinical Oncology. He is often an invited speaker at scientific conferences both Nationally and Internationally. He is on the Editorial Board of various peer reviewed journals.